Prevention of Breast Cancer-related Lymphedma With Tacrolimus

• Status: Active, not recruiting
• Trial end date: 2022-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

Breast cancer-related lymphedema is one of the most common and feared consequences of breast cancer treatment. Tacrolimus ointment may prevent lymphedema by inhibition of CD4+T cells.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Odense University Hospital
• Treatments: Tacrolimus

Criteria

Inclusion Criteria:

• Female

• Breast cancer with planned ALND

• postmenopausal or use of contraceptives

• good general health condition

• read and understand Danish

Exclusion Criteria:

• Pregnant, breastfeeding it wishing to conceive with the next year

• bilateral breast cancer

• known allergy to tacrolimus or macrolides

• known lymphedema

• other malignant disease apart from keratinocyte cancer

• in medical treatment for diabetes mellitus

• known psychiatric condition which may influence participation

• known renal or hepatic function